Skip to main content
. 2019 Aug 15;11(8):1187. doi: 10.3390/cancers11081187

Figure 1.

Figure 1

Serum hyaluronan (HA) is elevated in patients with chemoresistant disease. (a) HA serum levels (ng/mL) in serous ovarian cancer patients at initial diagnosis and following relapse with chemoresistant disease (n = 9). * significantly different from levels at diagnosis (p = 0.0039, Wilcoxon pair test). (b) HA serum levels (ng/mL) in serous ovarian cancer patients at initial diagnosis and following relapse with chemosensitive disease (n = 7, p = 0.219, Wilcoxon pair test).